Recent favorable reports of the use of the veratrum alkaloids in essential hypertension suggest the need for revaluation of the drug which had passed into "deserved oblivion."1
In 1946 Hite2 reported the first clinical evaluation of the use of the biologically standardized whole powdered drug. He observed in a series of 30 cases that 60 per cent had a fall of greater than 25 mm. of mercury in systolic pressure and 26.6 per cent a reduction of 20 mm. in diastolic pressure. Daily dosage varied from 15 to 30 Craw units.2a The only reactions noted were vomiting in 1 patient and headache in another. No effect of the drug was noted on occasional electrocardiograms.
More recently, Freis and his associates3 reported extensive studies on the hemodynamic effects and clinical use of veratrum viride in man. In their group of 34 ambulatory hypertensive patients, 30 (88 per
COE WS, BEST MM, KINSMAN JM. VERATRUM VIRIDE IN THE TREATMENT OF HYPERTENSIVE VASCULAR DISEASE. JAMA. 1950;143(1):5–7. doi:10.1001/jama.1950.02910360007003
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: